These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 282)

  • 1. [Combined use of bucolome and pyrazolone derivatives (II). Complex formation due to interaction between bucolome and pyrazolones].
    Nozaki M
    Nihon Yakurigaku Zasshi; 1975 Sep; 71(6):631-9. PubMed ID: 282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Combined use of bucolome and pyrazolone derivatives (1). Pharmacological activities and blood concentration].
    Nozaki M
    Nihon Yakurigaku Zasshi; 1975 Sep; 71(6):609-29. PubMed ID: 281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrazolone derivatives.
    Brogden RN
    Drugs; 1986; 32 Suppl 4():60-70. PubMed ID: 3552586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of bucolome in rats. Stability and biliary excretion of bucolome N-glucuronide.
    Mohri K; Uesawa Y; Uesugi T
    J Chromatogr B Biomed Sci Appl; 2001 Aug; 759(1):153-9. PubMed ID: 11499619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of bucolome and related barbiturate derivatives on the displacement of bilirubin from plasma albumin in vivo and in vitro.
    Yamamoto T; Adachi Y; Kuwahara I
    Gastroenterol Jpn; 1979 Oct; 14(5):483-91. PubMed ID: 42598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome.
    Takamura N; Maruyama T; Chosa E; Kawai K; Tsutsumi Y; Uryu Y; Yamasaki K; Deguchi T; Otagiri M
    Drug Metab Dispos; 2005 Apr; 33(4):596-602. PubMed ID: 15640375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance.
    Takahashi H; Kashima T; Kimura S; Murata N; Takaba T; Iwade K; Abe T; Tainaka H; Yasumori T; Echizen aH
    Drug Metab Dispos; 1999 Oct; 27(10):1179-86. PubMed ID: 10497145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Further production and characterization of antibodies reactive with pyrazolone derivatives.
    Takatori T; Yamaoka A
    J Immunol Methods; 1980; 35(1-2):147-55. PubMed ID: 7204986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug interactions. II. Binding of some pyrazolone and pyrazolidine derivatives to bovine serum albumin.
    Ozeki S; Tejima K
    Chem Pharm Bull (Tokyo); 1974 Jun; 22(6):1297-301. PubMed ID: 4472458
    [No Abstract]   [Full Text] [Related]  

  • 10. Sulfadimethoxine-bucolome interaction in rabbits: role of N4-acetylsulfadimethoxine, a major metabolite of sulfadimethoxine.
    Imamura Y; Mori H; Otagiri M
    Eur J Drug Metab Pharmacokinet; 1987; 12(3):169-73. PubMed ID: 2893735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the UDP-glucuronosyltransferase responsible for bucolome N-glucuronide formation in rats.
    Kanoh H; Okada K; Mohri K
    Pharmazie; 2010 Nov; 65(11):840-4. PubMed ID: 21155392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Displacement of bilirubin from adult and newborn serum albumin by a drug and fatty acid.
    Ivarsen R; Brodersen R
    Dev Pharmacol Ther; 1989; 12(1):19-29. PubMed ID: 2566458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The stereoselective effects of bucolome on the pharmacokinetics and pharmacodynamics of racemic warfarin.
    Matsumoto K; Ishida S; Ueno K; Hashimoto H; Takada M; Tanaka K; Kamakura S; Miyatake K; Shibakawa M
    J Clin Pharmacol; 2001 Apr; 41(4):459-64. PubMed ID: 11304904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of human neutrophil oxidative burst by pyrazolone derivatives.
    Costa D; Marques AP; Reis RL; Lima JL; Fernandes E
    Free Radic Biol Med; 2006 Feb; 40(4):632-40. PubMed ID: 16458194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and luminescence properties of pyrazolone derivatives and their terbium complexes.
    Xiao H; Jiang X; Li D; Wu L; Zhang W; Guo D
    Luminescence; 2015 Aug; 30(5):677-85. PubMed ID: 25352448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Therapeutic Journey of 5-Pyrazolones as a Versatile Scaffold: A Review.
    Sharma R; Chawla PA; Chawla V; Verma R; Nawal N; Gupta V
    Mini Rev Med Chem; 2021; 21(13):1770-1795. PubMed ID: 33397258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New thiazolidones-4 with pyrazolone-5 substituent as the potential NSAIDs.
    Lesyk R; Vladzimirska O; Zimenkovsky B; Horishny V; Nektegayev I; Solyanyk V; Vovk O
    Boll Chim Farm; 1998 Jun; 137(6):210-7. PubMed ID: 9713155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrazolones and analgesic asthma syndrome.
    Virchow C; Schmitz-Schumann M; Juhl-Schaub E
    Agents Actions Suppl; 1986; 19():291-301. PubMed ID: 3489358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Grafting of multiwalled carbon nanotubes with pyrazole derivatives: characterization, antimicrobial activity and molecular docking study.
    Metwally NH; Saad GR; Abd El-Wahab EA
    Int J Nanomedicine; 2019; 14():6645-6659. PubMed ID: 31686804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of the fluorescence of some newly synthesized europium complexes with pyrazolone derivatives.
    Qian DJ; Leng WN; Zhang Y; Chen Z; Van Houten J
    Spectrochim Acta A Mol Biomol Spectrosc; 2000 Dec; 56(14):2645-51. PubMed ID: 11145330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.